OPKO Health Inc. (NASDAQ: OPK) shares are 198.30% up in the year-to-date (YTD) period and have moved -7.49% or -$0.35 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +292.53% lower. Comparatively, the stock is -32.23% down YTD and 91.48% over the trailing 3-month period. If we look at the shorter duration, its week performance is -12.48% and -25.04% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
On March 02, 2018, JP Morgan recommended the OPK stock is a Underweight, while earlier, Piper Jaffray had Initiated the stock as a Overweight on November 25, 2019. 5 analysts offering the recommendations for the stock have a consensus rating of 1.80 to suggest that the OPK stock is a “Strong Buy. 0 of the 5 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $4.39 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $8.00. The forecasts give the OPKO Health Inc. stock a price target range of $10.00 on the higher side while at least one analyst think the stock could plunge to a low of $6.50. The two limits represent an upside potential of 56.1% or 32.46%.
Analysts estimate the earnings to increase 171.40% in the current quarter to $0.04, up from the -$0.11 reported in the same quarter a year ago. For the current year, earnings should grow to an average of $0.05, up 42.30% from -$0.37 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0.03 and $0.1. Wall Street estimates earnings per share to be at an average of $0.21 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 251 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 10,193,304 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 550,000 and 0 in purchases and sales respectively.
FROST PHILLIP MD ET AL, a CEO & Chairman at the company, bought 100,000 shares worth $0.24 million at $2.42 per share on Jun 02. The CEO & Chairman had earlier bought another 100,000 OPK shares valued at $0.23 million on Jun 03. The shares were bought at $2.27 per share. FROST PHILLIP MD ET AL (CEO & Chairman) bought 100,000 shares at $2.16 per share on May 28 for a total of $0.22 million while FROST PHILLIP MD ET AL, (CEO & Chairman) bought 250,000 shares on May 26 for $0.59 million with each share fetching $2.35.
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), on the other hand, is trading around $0.28 with a market cap of $49.53M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $Technology per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Sunesis Pharmaceuticals Inc. (SNSS) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
SNSS’s operating expenses over the recent quarter were at -$6.34 million. With this in place, we can see that the company’s diluted EPS declined -$0.06 on the year-over-year period, shrinking to -$0.09 as given in the last earnings report.
In terms of the balance sheet & cash flow as of Name, the total assets figure advanced to $25.51 million from $31.49 million over the previous quarter. The company’s free cash flow for the quarter was -$11.54 million.
Insiders have transacted a total of 1 times at Sunesis Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 1 times and accounting for 6,000 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 1.0 shares. Insiders now hold a total of ANSYS, Inc. shares after the latest sales, with GNSS net shares purchased.
Insiders own 0.18% of the company shares, while shares held by institutions stand at 24.60% with a share float percentage of 65.91M.